A case of rapid desensitization for rituximab-induced delayed hypersensitivity reaction
Allergy, Asthma & Respiratory Disease
; : 109-112, 2019.
Article
en Ko
| WPRIM
| ID: wpr-739510
Biblioteca responsable:
WPRO
ABSTRACT
Rituximab is a monoclonal antibody used for the treatment of B-cell malignancies, including diffuse large B-cell lymphoma. Infusion-related hypersensitivity reactions to rituximab is well known, and delayed hypersensitivity reactions to rituximab are also reported. Desensitization is commonly used to prevent immediate hypersensitivity reactions, but recently there have been cases of successful desensitization therapy for delayed hypersensitivity reactions. A 66-year-old patient who underwent rituximab treatment for diffuse large B-cell lymphoma showed repeated rituximab-induced delayed hypersensitivity reactions with whole body rashes. Intravenous rapid desensitization was performed by using a 1-bottle, 11-step protocol for 6 cycles and thereafter hypersensitivity reaction did not recur. We herein reported a case of delayed hypersensitivity reaction caused by rituximab, which was successfully desensitized using our 11-step protocol.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Linfocitos B
/
Linfoma de Células B
/
Desensibilización Inmunológica
/
Exantema
/
Rituximab
/
Hipersensibilidad
/
Hipersensibilidad Tardía
/
Hipersensibilidad Inmediata
Tipo de estudio:
Guideline
Límite:
Aged
/
Humans
Idioma:
Ko
Revista:
Allergy, Asthma & Respiratory Disease
Año:
2019
Tipo del documento:
Article